Apellis Pharmaceuticals experienced a significant boost in its shares, with a 14% increase to $36.40 in premarket trading. This surge was fueled by the company’s announcement of positive data from its extension study, which spanned 30 months of continuous treatment with the groundbreaking Syfovre pegcetacoplan injection.
Syfovre stands as the sole FDA-approved treatment for individuals suffering from geographic atrophy secondary to age-related macular degeneration. The recent findings further validate the long-term efficacy and safety of Syfovre and demonstrate its “robust and increasing effects” throughout the entire 30-month period, regardless of whether patients received monthly or every-other-month treatment.
Remarkably, the data revealed that Syfovre was able to reduce GA lesion growth by up to 45% in patients with nonsubfoveal lesions, effectively slowing down the progression of this debilitating condition.
It is worth noting that the safety profile of Syfovre remained consistent with the previously reported Phase 3 data throughout the course of the study. Notably, between months 24 and 30, no non-serious adverse events of ischemic optic neuropathy were reported in either treatment group, underscoring the drug’s well-tolerated nature. Only one serious adverse event was reported in the monthly treatment group, further establishing Syfovre’s overall safety record.
With these promising results, Apellis Pharmaceuticals continues to establish itself as a trailblazer in the field of ocular therapeutics. As more patients benefit from the life-changing effects of Syfovre, hopes for an improved quality of life soar.
